

Smoking and COVID-19

Scientific brief

30 June 2020



This is an update to the Scientific Brief entitled 'Smoking and COVID-19,' originally published on 26 May 2020. Since its publication, a study entitled 'Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19' by Mehra et al. has been retracted by the New England Journal of Medicine. This version of the Scientific Brief has removed the study from the review. The removal of this study from the review does not change the conclusions of the analysis.

Background

The harms of tobacco use are well-established. Tobacco causes 8 million deaths every year from cardiovascular diseases, lung disorders, cancers, diabetes, and hypertension.¹ Smoking tobacco is also a known risk factor for severe disease and death from many respiratory infections.²⁻⁴ In the COVID-19 pandemic, questions have been asked about clinical outcomes for smokers, and whether they are equally susceptible to infection, and if nicotine has any biological effect on the SAR-CoV-2 virus (the virus that causes COVID-19).⁵⁻⁷ At the time of writing, one clinical trial to test the effects of nicotine has been announced, but no trial registration record was found as of 12 May 2020.

This review therefore assesses the available peer-reviewed literature on the association between smoking and COVID-19, including 1) risk of infection by SARS-CoV-2; 2) hospitalization with COVID-19; and 3) severity of COVID-19 outcomes amongst hospitalized patients such as admission into intensive care units (ICU), use of ventilators and death.

Methods

A review was conducted on 12 May 2020 on smoking and COVID-19, using MEDLINE, EMBASE, Cochrane Library, and WHO Global Database. Quantitative primary research on adults or secondary analyses of such studies were included. Individual studies included in meta-analyses that were not otherwise identified in the search were sought.

Due to the preliminary nature of the many non-peer-reviewed reports issued during the COVID-19 pandemic, preprint repositories were deliberately excluded from this review.

Review of the evidence

Thirty-four peer-reviewed studies met the inclusion criteria. All included studies were in English. None examined tobacco use and the risk of infection or the risk of hospitalization. A total of 26 observational studies and eight meta-analyses were identified. All observational studies reported the prevalence of smoking amongst hospitalized COVID-19 patients. Two meta-analyses reported pooled prevalence of smoking in hospitalized patients using a subset of these studies (between 6 and 13 studies).

Eighteen of the 26 observational studies containing data on smoking status by severity of COVID-19 outcomes. Six meta-analyses were identified that examined the association between smoking and severity of COVID-19. Nine of the 18 studies were included in the six meta-analyses of smoking and severity (five to seven studies in each analysis), resulting in 1,604 sets of patient data being reported more than once. All data in the six meta-analyses come from patients in China.

What is the risk of smokers being infected by SARS-CoV-2?

There are currently no peer-reviewed studies that have evaluated the risk of SARS-CoV-2 infection among smokers. This research question requires well-designed population-based studies that control for age and relevant underlying risk factors.

What is the risk of smokers being hospitalized for COVID-19?

There are currently no peer-reviewed studies that directly estimate the risk of hospitalization with COVID-19 among smokers. However, 27 observational studies found that smokers constituted 1.4-18.5% of hospitalized adults.⁸⁻³² Two meta-analyses have been published which pooled the prevalence of smokers in hospitalized patients across studies based in China. The meta-analysis by Emami et al.³³ analysed data for 2986 patients and found a pooled prevalence of smoking of 7.6% (3.8% -12.4%) while Farsalinos et al.³⁴ analysed data for 5960 hospitalized patients and found a pooled prevalence of 6.5% (1.4% - 12.6%).

What is the risk of severe COVID-19 disease and death amongst smokers?

Meta-analyses:

Zhao et al.³⁵ analysed data from 7 studies (1726 patients) and found a statistically significant association between smoking and severity of COVID-19 outcomes amongst patients (Odds Ratio (OR) 2.0 (95% CI 1.3 – 3.1). The statistical significance disappeared when the largest study by Guan et al.¹³ was removed from the analysis (a sensitivity test to see the impact of a single study on the findings of the meta-analysis). An updated version of this meta-analysis which included an additional study remained significant when this same sensitivity test was applied however.³⁶ Zheng et al.³⁷ analysed data from 5 studies totalling 1980 patients and found a statistically significant association between smoking and COVID-19 severity when using a fixed effects model: OR: 2.0 (95% CI 1.3 – 3.2). Lippi et al.³⁸ analysed data from 5 studies totalling 1399 patients and found a non-significant association between smoking and severity. Guo et al.,³⁹ however, later identified errors in the calculation and concluded that this association was indeed statistically significant (OR 2.2 (95% CI 1.3 – 3.7). Vardavas et al.⁴⁰ analysed data from 5 studies totalling 1549 patients and calculated a relative risk that indicated a non-significant relationship between smoking and severity of COVID-19. However, the same authors found a statistically significant association between smoking status and primary endpoints of admission to Intensive Care Unit (ICU), ventilator use or death.

Individual studies not included in meta-analyses:

Nine studies were not included in any of the meta-analyses identified. One of these studies reported observational data for 7162 people in hospital and outpatient settings in the United States of America but did not include any statistical analysis of association.¹⁰ Another study of 323 hospitalized patients in Wuhan, China, reported a statistically significant association between smoking and severity of disease (OR 3.5 (95% CI 1.2 – 10.2)).¹⁵ Kozak et al.⁴¹ found a statistically significant association between smoking and ICU admission and mortality amongst 226 patients in Toronto, Canada. The remaining six studies were small case series (ranging from 11 to 145 people) that reported no statistically significant associations between smoking status and severity of COVID-19,^{8, 11, 18, 27, 42} apart from Yu et al.⁴³ who reported on a study of 70 patients a statistically significant OR of 16.1 (95% CI 1.3 – 204.2) in a multivariate analysis examining the association between smoking and the exacerbation of pneumonia after treatment.

Limitations

Hospital based studies that report patient characteristics can suffer from several limitations, including poor data quality. Collecting smoking history is challenging in emergency contexts and severity of disease is often not clearly defined and is inconsistent across studies. Such studies are also prone to significant sampling bias. Characteristics of those who are hospitalized will differ by country and context depending on available resources, access to hospitals, clinical protocols and possibly other factors not considered in the studies. Further, most studies did not make statistical adjustments to account for age and other confounding factors.

Well-designed population-based studies are needed to address questions about the risk of infection by SARS-CoV-2 and the risk of hospitalization with COVID-19.

Conclusions

At the time of this review, the available evidence suggests that smoking is associated with increased severity of disease and death in hospitalized COVID-19 patients. Although likely related to severity, there is no evidence to quantify the risk to smokers of hospitalization with COVID-19 or of infection by SARS-CoV-2 was found in the peer-reviewed literature. Population-based studies are needed to address these questions.

Related WHO Recommendations

Given the well-established harms associated with tobacco use and second-hand smoke exposure,² WHO recommends that tobacco users stop using tobacco. Proven interventions to help users quit include toll-free quit lines, mobile text-messaging cessation programmes, nicotine replacement therapies and other approved medications.

References

1. Global Burden of Disease: GBD Compare Tool, 2020 [Available from: <https://vizhub.healthdata.org/gbd-compare/>] Accessed: April 27 2020.
2. A report of the Surgeon General. The health consequences of smoking: 50 years of progress. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
3. Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. BMC public health. 2018;18(1):574. <https://doi.org/10.1186/s12889-018-5484-8>
4. Han L, Ran J, Mak YW, Suen LK, Lee PH, Peiris JSM, et al. Smoking and Influenza-associated Morbidity and Mortality: A Systematic Review and Meta-analysis. Epidemiology. 2019;30(3):405-17. <https://doi.org/10.1097/EDE.0000000000000984>
5. Miyara M, Tubach F, Pourcher V, Morelot-Panzini C, Pernet J, Lebbah S, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios. 2020. <https://doi.org/10.32388/WPP19W.3>
6. Fontanet A, Tondeur L, Madec Y, Grant R, Besombes C, Jolly N, et al. Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv.2020:Apr 23. <https://doi.org/10.1101/2020.04.18.20071134>

7. Changeux J, Amoura Z, Rey F, Miyara M. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. *Qeios*. 2020. <https://doi.org/10.32388/FXGOSE>
8. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. *Infection*, 2020. Apr 28:1-9. <https://doi.org/10.1007/s15010-020-01432-5>
9. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091. <https://doi.org/10.1136/bmj.m1091>
10. Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. *Morbidity and Mortality Weekly Report*. 2020;69(13):382-6.
11. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. *Allergy*. 2020. 0(0):1-11 <https://doi.org/10.1111/all.14289>
12. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *The European Respiratory Journal*. 2020. 55: 2000547 <https://doi.org/10.1183/13993003.00547-2020>
13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The New England Journal of Medicine*. 2020;382(18):1708-20. <https://doi.org/10.1056/NEJMoa2002032>
14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*. 2020. Mar 27. <https://doi.org/10.1001/jamacardio.2020.1017>
15. Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. *Clinical Infectious Diseases* : an official publication of the Infectious Diseases Society of America. 2020. May 3. <https://doi.org/10.1093/cid/ciaa539>
16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
17. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. *Gut*. 2020.69:1002-1009. <http://dx.doi.org/10.1136/gutjnl-2020-320926>
18. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *Journal of Korean Medical Science*. 2020;35(13). <https://doi.org/10.3346/jkms.2020.35.e142>
19. Lian, Jiangshan, Jin, Xi Analysis of Epidemiological and Clinical Features in Older Patients with Coronavirus Disease 2019 (COVID-19) Outside Wuhan. *Clinical Infectious Diseases*. 2020. Mar 25. <https://doi.org/10.1093/cid/ciaa242>
20. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *The Lancet Oncology*. 2020;21(3):335-7. [https://doi.org/10.1016/S1470-2045\(20\)30096-6](https://doi.org/10.1016/S1470-2045(20)30096-6)
21. Liu J, Chen T, Yang H, Cai Y, Yu Q, Chen J, et al. Clinical and radiological changes of hospitalised patients with COVID-19 pneumonia from disease onset to acute exacerbation: a multicentre paired cohort study. *European Radiology*. 2020. May 8:1-7. <https://doi.org/10.1007/s00330-020-06916-4>
22. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chinese Medical Journal*. 2020;133(9):1032-8. <https://doi.org/10.1097/CM9.0000000000000775>
23. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clinical Infectious Diseases* : an official publication of the Infectious Diseases Society of America. 2020. Mar 16. [ciaa270. https://doi.org/10.1093/cid/ciaa270](https://doi.org/10.1093/cid/ciaa270)
24. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. *Critical Care*. 2020; 24(1):108. <https://doi.org/10.1186/s13054-020-2833-7>
25. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *Journal of Medical Virology*. 2020. <https://doi.org/10.1002/jmv.25783>
26. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. 2020. 8(5): 475-481. [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5)
27. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020. Feb 19. <https://doi.org/10.1111/all.14238>
28. Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 2020;94:81-7. <https://doi.org/10.1016/j.ijid.2020.03.040>
29. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-62. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
30. Zhou Y, Zhang Z, Tian J, Xiong S. Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus. *Annals of Palliative Medicine*. 2020;9(2):428-36. <https://doi.org/10.21037/apm.2020.03.26>
31. Wu J, Wu X, Zeng W, Guo D, Fang Z, Chen L, et al. Chest CT Findings in Patients with Coronavirus Disease 2019 and Its Relationship with Clinical Features. *Investigative Radiology*. 2020;55(5):257-61. <https://doi.org/10.1097/RLI.0000000000000670>
32. Zhu W, Xie K, Lu H, Xu L, Zhou S, Fang S. Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China. *Journal of Medical Virology*. 2020. Mar 13. <https://doi.org/10.1002/jmv.25763>

33. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Archives of Academic Emergency Medicine. 2020. 8(1): e35
34. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Internal and Emergency Medicine. 2020. May 9;1-8. <https://doi.org/10.1007/s11739-020-02355-7>
35. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis. Journal of Medical Virology. 2020. Apr 15. <https://doi.org/10.1002/jmv.2588>
36. Guo FR. Smoking links to the severity of Covid-19: An update of a meta-analysis. Journal of Medical Virology. 2020. May 5. <https://doi.org/10.1002/jmv.25967>
37. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. The Journal of Infection. 2020. Apr 23;S0163-4453(20)30234-6. <https://doi.org/10.1016/j.jinf.2020.04.021>
38. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). European Journal of Internal Medicine. 2020;75:107-8. <https://doi.org/10.1016/j.ejim.2020.03.014>
39. Guo FR. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis. Tobacco induced diseases. 2020;18:37. <https://doi.org/10.18332/tid/121915>
40. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tobacco induced diseases. 2020. 18(March):20. <https://doi.org/10.18332/tid/119324>
41. Kozak R, Prost K, Yip L, Williams V, Leis JA, Mubareka S. Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario. Journal of Clinical Virology. 2020. May 29. 126: 104338. doi:[10.1016/j.jcv.2020.104338](https://doi.org/10.1016/j.jcv.2020.104338)
42. Zheng Y, Xiong C, Liu Y, Qian X, Tang Y, Liu L, et al. Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei Province in 2020. Pharmacological research. 2020;157:104821. <https://doi.org/10.3389/fcimb.2020.00284>
43. Yu T, Cai S, Zheng Z, Cai X, Liu Y, Yin S, et al. Association Between Clinical Manifestations and Prognosis in Patients with COVID-19. Clinical Therapeutics. 2020. Apr 27. <https://doi.org/10.1016/j.clinthera.2020.04.009>

WHO continues to monitor the situation closely for any changes that may affect this scientific brief. Should any factors change, WHO will issue a further update. Otherwise, this scientific brief document will expire 2 years after the date of publication.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24512

